You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Sanofi’s Sarclisa combination shows positive results in multiple myeloma patients

The latest results from the phase 3 IKEMA clinical trial evaluating Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone demonstrated an unprecedented median progression free survival (mPFS) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy.